摘要
目的检测从临床标本中分离的43株奇异变形杆菌对16种抗菌药物的体外活性,以及这些杆菌产超广谱β-内酰胺酶、AmpC酶、金属β-内酰胺酶的情况,正确指导临床合理使用抗生素。方法用API-20E对菌株进行鉴定,双纸片协同试验和确证试验筛选超广谱β-内酰胺酶,纸片扩散法检测AmpC酶,改良Hodge试验检测金属β-内酰胺酶,药敏试验采用标准的纸片扩散法。结果奇异变形杆菌的产酶率为20．9％(9/43)。其中,超广谱β-内酰胺酶为18．6％(8/43),AmpC酶为 2．3％(1/43),金属β-内酰胺酶为0。三代头孢菌素、四代头孢菌素、氨曲南、头孢西啶、亚胺培南、阿米卡星和左氧氟沙星的敏感率均大于80％。结论实验室有必要加强对产β-内酰胺酶奇异变形杆菌的检测。三代头孢菌素、四代头孢菌素、氨曲南、头孢西啶、亚胺培南、阿米卡星和左氧氟沙星是治疗奇异变形杆菌感染的首选药物。
Objective To determine the activity of 16 antibacterials against 43 strains of Proteus mirabilis isolated from clinical specimens so as to guide the rational application of antibiotics. Methods Identification of the strains was performed by the API 20E. Screening extended-spectrum β-lactama ses-producing isolates by a double-disk synergy test and a phenotypic confirmatory test, AmpC β-lacta mases-producing isolates were determined by the disk diffusion method, metallo-β-lactamases-produ cing isolates was determined by the modified Hodge test. Antibiotic susceptibilities of P. mirabilis isolates were determined by standard disk diffusion. Results The rate of producing β-lactamases of P. mirabilis was 20. 9%(9/43) , extended-spectrum β-lactamases was 18. 6% (8/43), AmpC β-lactamases was 2. 3%(l/43), metallo-β-lactamases was 0. The sensitive rate of P. mirabilis clinical isolates to third-generation cephalosporins, fourth-generation cephalosporins, aztreonam, cefoxitin, imipenem, amikacin and levofloxacin were more than 80%. Conclusion Clinical laboratories must strengthen to determine P. mirabilis of lactamases-producing isolates. Third-generation cephalosporins, fourth-generation cephalosporins, aztreonam, cefoxitin, imipenem, amikacin and levofloxacin were the first candidate for the infectious conditions caused by the P. mirabilis.
出处
《检验医学与临床》
CAS
2005年第1期3-4,6,共3页
Laboratory Medicine and Clinic
